Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.46 |
| ▸ | ITGB2 | P05107 | 6/20 | 0.41 |
| ▸ | ICAM1 | P05362 | 6/20 | 0.41 |
| ▸ | ITGAL | P20701 | 6/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.37 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23978958 | 1.00 | TRPV1 (0.46) | TRPV1ITGB2ICAM1ITGALEPHX2 | |
| SCHEMBL26105654 | 1.00 | TRPV1 (0.46) | TRPV1ITGB2ICAM1ITGALEPHX2 | |
| SCHEMBL30336947 | 1.00 | TRPV1 (0.46) | TRPV1ITGB2ICAM1ITGALEPHX2 | |
| SCHEMBL23978950 | 0.94 | EPHX2 (0.45) | TRPV1ITGB2ICAM1ITGALEPHX2 | |
| SCHEMBL30337050 | 0.94 | EPHX2 (0.45) | TRPV1ITGB2ICAM1ITGALEPHX2 | |
| SCHEMBL26106503 | 0.94 | EPHX2 (0.45) | TRPV1ITGB2ICAM1ITGALEPHX2 | |
| SCHEMBL23978559 | 0.94 | EPHX2 (0.45) | TRPV1ITGB2ICAM1ITGALEPHX2 | |
| SCHEMBL23978744 | 0.94 | EPHX2 (0.45) | TRPV1ITGB2ICAM1ITGALEPHX2 | |
| SCHEMBL26476268 | 0.94 | TRPV1 (0.46) | TRPV1ITGB2ICAM1ITGAL | |
| SCHEMBL26476152 | 0.94 | TRPV1 (0.46) | TRPV1ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-29 | — | — | US | disclosed |
| WO-2021222789-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | ITGB1, ITGB2, ITGA2 | TRPV1 2681/4885ITGB2 2/4885ICAM1 21/4885 |
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | ITGB1, ITGB2, ITGA2 | TRPV1 2681/4885ITGB2 2/4885ICAM1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.